Aceso Life Science's (HKG:0474) attributable loss narrowed to HK$137 million in the half-year ended Sept. 30 from HK$207 million in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the construction machinery company narrowed to HK$0.0191 from HK$0.0285 in the previous year.
Revenue declined to HK$109 million from HK$113 million a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.